DRW Securities’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-9,200
Closed -$511K 1542
2025
Q3
$511K Buy
+9,200
New +$539K 0.01% 600
2025
Q2
Sell
-135,400
Closed -$9.4M 1216
2025
Q1
$9.4M Buy
135,400
+117,400
+652% +$9.7M 0.26% 54
2024
Q4
$1.55M Buy
18,000
+10,400
+137% +$1.12M 0.05% 173
2024
Q3
$905K Buy
+7,600
New +$1.01M 0.03% 299
2023
Q4
Sell
-15,200
Closed -$1.38M 412
2023
Q3
$1.38M Buy
+15,200
New +$1.34M 0.03% 115

Other funds holding NVO

DRW Securities's NVO Position: Q2 2026 in Review

DRW Securities reduced its Novo Nordisk (NVO) stake by 77% in Q2 2026, selling an estimated $930K and leaving 6,628 shares worth $318K. The position accounts for 0.01% of the portfolio, ranked #590.

DRW Securities first reported a position in NVO in Q3 2015 and has held it in 18 quarters since. The position peaked at $10.3M in Q3 2024. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • DRW Securities held 6,628 shares of Novo Nordisk worth $318K as of Q2 2026.
  • DRW Securities sold 21,647 Novo Nordisk shares in Q2 2026, an estimated $930K.
  • Novo Nordisk made up 0.01% of DRW Securities's portfolio in Q2 2026, its #590 holding.
  • DRW Securities first reported a position in Novo Nordisk in Q3 2015 and has held it in 18 quarters since.
  • DRW Securities's Novo Nordisk position peaked at $10.3M in Q3 2024.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on DRW Securities's 13F filing for Q2 2026, filed 14 Aug 2026.